In part one of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) discusses the challenges of CAR-T therapy for follicular lymphoma and the advantages of MB-106, a third-generation, CD20-targeted, autologous CAR-T cell therapy over earlier generation CAR-T therapies.
Abstract S207: ‘EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL)’ was presented at the EHA 2022 annual meeting.
Questions
- What have been the benefits and limitations of CAR-T therapy for follicular lymphoma? (00:12-01:05)
- What is MB-106 and what are its advantages over earlier generation CAR-T therapies? (01:05-01:58)
Disclosures: Mazyar Shadman is consultant for, has received grant/research support from and is part of the Advisory Board for: Abbvie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squibb, Morphosys/Incyte, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, Merck, Fate therapeutics, MEI pharma and Atara Biotherapeutic. Research Funding: Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, Beigene, AstraZeneca, Sunesis,Atara Biotherapeutics, Genmab and Morphosys/Incyte.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA)
